Endocrine Testing Market Size, Trends, Share, Growth | Report 2023-2032
The global endocrine testing market size was estimated at around USD 2.55 billion in 2022 and it is projected to hit around USD 5.68 billion by 2032, growing at a CAGR of 8.36% from 2023 to 2032.
Key Pointers
| Report Coverage | Details |
| Market Size in 2022 | USD 2.55 billion |
| Revenue Forecast by 2032 | USD 5.68 billion |
| Growth rate from 2023 to 2032 | CAGR of 8.36% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Abbott Laboratories; AB Sciex; Agilent Technologies Inc.; bioMerieux SA, Bio-Rad Laboratories; DiaSorin S.p.A.; F.Hoffmann-La Roche Ltd; Laboratory Corporation of America Holdings; Quest Diagnostics Incorporated; Ortho Clinical Diagnostics; |
The prevalence of diabetes, thyroid, and obesity worldwide has resulted in government funding initiatives for increasing research activities and rapid technological developments caused launch of multiple detection tests as well as novel products by life science companies. The increase in research and development (R&D) in medical and clinical diagnostics’ field, the availability of advanced technologies such as biosensors and point-of-care to cater to the growing awareness of routine health monitoring are few factors attributing to the endocrine testing market growth.
The demand for endocrine testing is rising as there is increased health consciousness and a growing prevalence of lifestyle diseases among the adult individuals. This upsurge in awareness has contributed to increase of home healthcare and point-of-care (POC) devices with faster and efficient outputs. The home healthcare & POC devices are easy to operate and are cost effective alternatives targeting the adult as well the increasing geriatric population. According to the International Diabetes Federation, 537 million people are already living with diabetes in 2021, and this number is projected to shoot to 643 and 783 million by 2030 and 2045 respectively. These disease projections will directly impact the endocrine testing market and will result in a dramatic growth in the years to come.
With the growing diseased population, the number of tests employed for endocrinology has organically increased. This increase necessitated the need of many new technological advancements for faster and reliable results. For instance, the coupling of mass spectroscopy with liquid chromatography (LC/MS) or tandem mass spectrometry (MS/MS) provides results with better precision and accuracy. Moreover, companies like Agilent Technologies, Inc. are also focusing on developing new alternative technologies for analysis, such as use of LC-ICP-MS for more robust thyroid hormone testing. Such technological developments create huge opportunities for the existing & emerging players, and are expected to fuel the endocrine testing market growth tremendously.
However, the lack of skilled & trained professionals limits the accurate diagnosis restricts the market growth. As endocrine function testing requires sample handling & preparation stages, this necessitates skilled as well as technical expertise. The lack of technically strong personnel eventually limits the quality of endocrine testing and results in poor patient outcomes.
Endocrine Testing Market Segmentations:
By Test Type
By Technology
By End-user
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Endocrine Testing Market
5.1. COVID-19 Landscape: Endocrine Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Endocrine Testing Market, By Test Type
8.1. Endocrine Testing Market, by Test Type, 2023-2032
8.1.1 Estradiol (E2) Test
8.1.1.1. Market Revenue and Forecast (2019-2032)
8.1.2. Follicle Stimulating Hormone (FSH) Test
8.1.2.1. Market Revenue and Forecast (2019-2032)
8.1.3. Human Chorionic Gonadotropin (hCG) Hormone Test
8.1.3.1. Market Revenue and Forecast (2019-2032)
8.1.4. Luteinizing Hormone (LH) Test
8.1.4.1. Market Revenue and Forecast (2019-2032)
8.1.5. Dehydroepiandrosterone Sulfate (DHEAS) Test
8.1.5.1. Market Revenue and Forecast (2019-2032)
8.1.6. Progesterone Test
8.1.6.1. Market Revenue and Forecast (2019-2032)
8.1.7. Testosterone Test
8.1.7.1. Market Revenue and Forecast (2019-2032)
8.1.8. Thyroid Stimulating Hormone (TSH) Test
8.1.8.1. Market Revenue and Forecast (2019-2032)
8.1.9. Prolactin Test
8.1.9.1. Market Revenue and Forecast (2019-2032)
8.1.10. Cortisol Test
8.1.10.1. Market Revenue and Forecast (2019-2032)
8.1.11. Insulin Test
8.1.11.1. Market Revenue and Forecast (2019-2032)
8.1.12. Others
8.1.12.1. Market Revenue and Forecast (2019-2032)
Chapter 9. Global Endocrine Testing Market, By Technology
9.1. Endocrine Testing Market, by Technology, 2023-2032
9.1.1. Mass Spectroscopy
9.1.1.1. Market Revenue and Forecast (2019-2032)
9.1.2. Immunoassay
9.1.2.1. Market Revenue and Forecast (2019-2032)
9.1.3. Chromatography
9.1.3.1. Market Revenue and Forecast (2019-2032)
9.1.4. Nucleic Acid Based
9.1.4.1. Market Revenue and Forecast (2019-2032)
Chapter 10. Global Endocrine Testing Market, By End-user
10.1. Endocrine Testing Market, by End-user, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2019-2032)
10.1.2. Commercial Laboratories
10.1.2.1. Market Revenue and Forecast (2019-2032)
10.1.3. Ambulatory Care Centers
10.1.3.1. Market Revenue and Forecast (2019-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2019-2032)
Chapter 11. Global Endocrine Testing Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.1.2. Market Revenue and Forecast, by Technology (2019-2032)
11.1.3. Market Revenue and Forecast, by End-user (2019-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.1.4.2. Market Revenue and Forecast, by Technology (2019-2032)
11.1.4.3. Market Revenue and Forecast, by End-user (2019-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.1.5.2. Market Revenue and Forecast, by Technology (2019-2032)
11.1.5.3. Market Revenue and Forecast, by End-user (2019-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.2.2. Market Revenue and Forecast, by Technology (2019-2032)
11.2.3. Market Revenue and Forecast, by End-user (2019-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.2.4.2. Market Revenue and Forecast, by Technology (2019-2032)
11.2.4.3. Market Revenue and Forecast, by End-user (2019-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.2.5.2. Market Revenue and Forecast, by Technology (2019-2032)
11.2.5.3. Market Revenue and Forecast, by End-user (2019-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.2.6.2. Market Revenue and Forecast, by Technology (2019-2032)
11.2.6.3. Market Revenue and Forecast, by End-user (2019-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.2.7.2. Market Revenue and Forecast, by Technology (2019-2032)
11.2.7.3. Market Revenue and Forecast, by End-user (2019-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.3.2. Market Revenue and Forecast, by Technology (2019-2032)
11.3.3. Market Revenue and Forecast, by End-user (2019-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.3.4.2. Market Revenue and Forecast, by Technology (2019-2032)
11.3.4.3. Market Revenue and Forecast, by End-user (2019-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.3.5.2. Market Revenue and Forecast, by Technology (2019-2032)
11.3.5.3. Market Revenue and Forecast, by End-user (2019-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.3.6.2. Market Revenue and Forecast, by Technology (2019-2032)
11.3.6.3. Market Revenue and Forecast, by End-user (2019-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.3.7.2. Market Revenue and Forecast, by Technology (2019-2032)
11.3.7.3. Market Revenue and Forecast, by End-user (2019-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.4.2. Market Revenue and Forecast, by Technology (2019-2032)
11.4.3. Market Revenue and Forecast, by End-user (2019-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.4.4.2. Market Revenue and Forecast, by Technology (2019-2032)
11.4.4.3. Market Revenue and Forecast, by End-user (2019-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.4.5.2. Market Revenue and Forecast, by Technology (2019-2032)
11.4.5.3. Market Revenue and Forecast, by End-user (2019-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.4.6.2. Market Revenue and Forecast, by Technology (2019-2032)
11.4.6.3. Market Revenue and Forecast, by End-user (2019-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.4.7.2. Market Revenue and Forecast, by Technology (2019-2032)
11.4.7.3. Market Revenue and Forecast, by End-user (2019-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.5.2. Market Revenue and Forecast, by Technology (2019-2032)
11.5.3. Market Revenue and Forecast, by End-user (2019-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.5.4.2. Market Revenue and Forecast, by Technology (2019-2032)
11.5.4.3. Market Revenue and Forecast, by End-user (2019-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Test Type (2019-2032)
11.5.5.2. Market Revenue and Forecast, by Technology (2019-2032)
11.5.5.3. Market Revenue and Forecast, by End-user (2019-2032)
Chapter 12. Company Profiles
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AB Sciex
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Agilent Technologies Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. bioMerieux SA
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bio-Rad Laboratories
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. DiaSorin S.p.A.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. F.Hoffmann-La Roche Ltd
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Laboratory Corporation of America Holdings
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Quest Diagnostics Incorporated
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Ortho Clinical Diagnostics
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers